Angiotensin receptor blocker

Guidelines strongly recommend patients with heart failure with reduced ejection fraction ( HFrEF ) be treated with multiple medications proven...


Data from the TRANSITION study presented at the European Society of Cardiology ( ESC ) Congress in Munich ( Germany...


Anthracycline-induced cardiotoxicity was first reported in early 1970s. Since then, there has been increasing recognition of its association with poor...


The new drug LCZ696 is a treatment for chronic heart failure. LCZ696 is better than conventional drugs at reducing cardiac...


Compared with traditional chemotherapy, targeted cancer therapy is a novel strategy in which key molecules in signaling pathways involved in...


The FDA ( Food and Drug Administration ) has strengthened the existing warning about the risk of acute kidney injury...


In the prospective, open-label, non-interventional, multicenter RESPONSIfVE study, the effectiveness, response rates and tolerability of Ivabradine ( Corlentor, Procoralan )...


A study assessed whether the benefit of Sacubitril / Valsartan ( Entresto ) therapy varied with clinical stability. Despite the benefit...


Hypertension is a common diabetes comorbidity that affects the majority of patients, with the prevalence depending on type of diabetes,...


A study has tested the hypothesis that risk factor pattern, treatment and prognosis differ between men and women with heart...


Sudden cardiac death ( SCD ) is a leading cause of mortality in patients with cardiomyopathy. Although angiotensin-converting enzyme inhibitors...


Entresto ( Sacubitril / Valsartan ), previously known as LCZ696 has been approved by Health Canada for the treatment of...


A post-hoc analysis of PARADIGM-HF data has demonstrated that fewer heart failure patients with reduced ejection fraction ( HFrEF...


The combination drug Valsartan / Sacubitril known as LCZ696 ( Entresto ) significantly reduced aortic systolic blood pressure and pulse...


The PARADIGM-HF ( Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and Morbidity in Heart Failure...


The fixed-dose combination of any two antihypertensive drugs from different drug classes is typically more effective in reducing blood pressure...


The first in class angiotensin receptor neprilysin inhibitor ( ARNI ), LCZ696 has been shown to reduce levels of N-terminal...


Elevated high-sensitivity troponin is associated with increasing disease severity in patients with stable heart failure with reduced ejection fraction, but...


The first in class angiotensin receptor neprilysin inhibitor, LCZ696 has been shown to reduce levels of N-terminal pro-brain natriuretic peptide...


Angiotensin converting enzyme inhibitors ( ACE inhibitors ) and angiotensin receptor blockers ( ARBs; sartans ) are widely prescribed for...